title: Phase I trials of targeted anticancer drugs: a need to refocus.
abstract: As cancer therapy progresses through the development of molecularly targeted drugs, the focus of Phase I trials needs to shift towards investigating end points that could guide more effective trial design, dosing and choice of tumour setting for Phase II studies.
authors.affiliation: Case Comprehensive Cancer Center, Taussig Cancer Institute R40, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA. bordene@ccf.org
authors.forename: Ernest C
authors.initials: EC
authors.lastname: Borden
authors.forename: Afshin
authors.initials: A
authors.lastname: Dowlati
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D017321:Clinical Trials, Phase I as Topic; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D012107:Research Design
chemical_list: D000970:Antineoplastic Agents